BestHealth4U (BH4U), a Portuguese startup focused on the R&D of medical adhesive technologies for the skin, today announced the close of its $1 million Seed financing round to fuel the journey to market of its first product, Bio2Skin. Bio2Skin is a patented innovative adhesive technology that will be integrated into products developed by manufacturers that produce medical adhesives and medical devices for continuous use.
After a pre-seed investment led by Portugal Ventures, this round of investment, led by Lince Capital, a Portuguese Venture Capital, BH4U will use the financing to complete the regulatory process in Europe and the USA, expand its team, accelerate its go-to-market efforts, and scale its current partnerships with adhesive and medical device manufacturers worldwide.
Sónia Ferreira, founder and CEO of BH4U, was diagnosed with a bladder malformation that led to a stoma when she was seven years old; since then, she has lived with skin problems due to the continued use of medical devices attached to her skin. Developing a solution to solve this problem became a priority for Sónia, and she founded BH4U in 2017.
“BH4U was founded with the mission to enable patients like me to live their life with dignity in their hardest times,” said Sónia Ferreira, BH4U’s CEO.“This makes Bio2Skin a unique product since patients benefit from its technology. It prevents further complications in their treatments that usually derive from an allergic reaction to the medical adhesives, keeping all costs to a minimum,” added Sónia.
BestHealth4U is driven by the experience of its founder Sónia Ferreira, who has managed a stoma since childhood. She could never find a pouch adhesive that was comfortable, flexible and didn’t damage her skin. BestHealth4U was founded in 2017 to develop next-generation technologies for skin-interacting medical devices that improve one’s health and quality of life, maintaining the skin healthy by using sustainable biomaterials: https://besthealth4u.pt/
About Portugal Ventures:
Portugal Ventures, part of the Grupo Banco Português de Fomento, has 184 million euros under management and more than 140 companies in its portfolio. Since 2012, Portugal Ventures has invested 171 million euros in 180 new companies: https://www.portugalventures.pt/en/
About Lince Capital:
Lince Capital is an independent venture capital company, registered and regulated by the Portuguese Securities Market Commission (CMVM), established in 2016. Lince Capital operates in the establishment and management of venture capital funds and specialized investment funds with the aim of financing and supporting business opportunities with high growth capacity: https://lince-capital.com/en/